Janus Henderson Group
BHVN

Janus Henderson Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Janus Henderson Group’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-549,664
Closed -$83.1M – 2649
2022
Q3 		$83.1M Sell
549,664
-525,802
-49% -$77.9M 0.06% 263
2022
Q2 		$157M Sell
1,075,466
-1,630,686
-60% -$208M 0.11% 193
2022
Q1 		$321M Buy
2,706,152
+1,299,597
+92% +$162M 0.15% 155
2021
Q4 		$194M Buy
1,406,555
+641,180
+84% +$81.5M 0.08% 237
2021
Q3 		$106M Buy
765,375
+27,480
+4% +$3.43M 0.05% 349
2021
Q2 		$71.6M Buy
737,895
+19,855
+3% +$1.61M 0.03% 464
2021
Q1 		$49.1M Buy
+718,040
New +$58.1M 0.02% 555
2019
Q2 		– Sell
-1,251,607
Closed -$64.4M – 1442
2019
Q1 		$64.4M Sell
1,251,607
-1,892,151
-60% -$81.7M 0.04% 514
2018
Q4 		$116M Sell
3,143,758
-193,158
-6% -$6.96M 0.07% 308
2018
Q3 		$125M Buy
3,336,916
+37,616
+1% +$1.38M 0.07% 335
2018
Q2 		$130M Sell
3,299,300
-96,830
-3% -$3.07M 0.07% 318
2018
Q1 		$87.5M Buy
3,396,130
+2,416,021
+247% +$72.2M 0.05% 403
2017
Q4 		$26.4M Buy
980,109
+291,200
+42% +$8.02M 0.02% 686
2017
Q3 		$25.8M Buy
688,909
+43,166
+7% +$1.31M 0.02% 680
2017
Q2 		$16.1M Buy
+645,743
New +$14.9M 0.01% 785

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Janus Henderson Group's BHVN Position: Q4 2022 in Review

Janus Henderson Group sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 549,664 shares — an estimated $83.1M sold.

Janus Henderson Group first reported a position in BHVN in Q2 2017 and held it in 15 quarters. The position peaked at $321M in Q1 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Janus Henderson Group reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Janus Henderson Group sold 549,664 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $83.1M.
  • Janus Henderson Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 15 quarters.
  • Janus Henderson Group's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $321M in Q1 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Janus Henderson Group's 13F filing for Q4 2022, filed 14 Feb 2023.